Literature DB >> 27034420

Long-awaited news for hepatic veno-occlusive disease.

Sally Arai1.   

Abstract

In this issue of Blood, Palomo et al provide new insight into the mechanism of action of defibrotide as an endothelial protective agent, while Richardson et al present the encouraging final results of the phase 3 clinical study of defibrotide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement in day +100 survival after hematopoietic cell transplantation (HCT) compared with historical control.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27034420     DOI： 10.1182/blood-2016-02-694943

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  3 in total

1.  Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant.

Authors:  Maria Sola; Valkal Bhatt; Meighan Palazzo; Kathleen E Cavalier; Sean M Devlin; Molly Maloy; Juliet N Barker; Hugo Castro-Malaspina; David Chung; Parastoo B Dahi; Ann A Jakubowski; Heather Landau; Esperanza B Papadopoulos; Miguel-Angel Perales; Craig Sauter; Roni Tamari; Nancy A Kernan; Sergio Giralt; James W Young; Jenna D Goldberg; Doris M Ponce
Journal:  Bone Marrow Transplant       Date:  2022-04-27       Impact factor: 5.174

Review 2.  Defibrotide in the treatment of hepatic veno-occlusive disease.

Authors:  Alessandro Fulgenzi; Maria Elena Ferrero
Journal:  Hepat Med       Date:  2016-10-31

3.  Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.

Authors:  Lijie Zhang; Qing Li; Joyman Makamure; Dan Zhao; Ziyi Liu; Chuansheng Zheng; Bin Liang
Journal:  BMC Gastroenterol       Date:  2021-01-10       Impact factor: 3.067
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.